ClinicalTrials.gg
CompletedNCT03238911Updated Feb 25, 2020Results posted

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

A Phase 3 interventional study of Iron isomaltoside/ferric derisomaltose and Ferric carboxymaltose in Iron Deficiency Anaemia and Iron Deficiency Anemia, sponsored by Pharmacosmos A/S. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-25.

Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 9 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.

Enrollment
15th of 32
123 · median 121
Started
2017
with 4 others
Phase 3
18 of 32
4 open now
Registered
14th of 32
by date
Lead sponsor
13 of 32
Pharmacosmos A/S

Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 15th largest by enrollment, is one of 5 that started in 2017, is one of 18 in phase 3, and was the 14th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

9 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).

Read the detailed description

This trial was designed to evaluate the effect of IV iron isomaltoside/ferric derisomaltose compared with IV ferric carboxymaltose on s-phosphate in subjects with IDA caused by different etiologies.

The subjects received either a single intravenous (IV) dose of iron isomaltoside/ferric derisomaltose (1000 mg at baseline) or two IV doses of ferric carboxymaltose (one dose 750 mg at baseline and a second dose 750 mg on day 7; cumulative dose: 1500 mg). The study subjects were monitored for up to 35 days from baseline.

03

Conditions studied

  • Iron Deficiency Anaemia
  • Iron Deficiency Anemia

Keywords

  • Iron Deficiency Anaemia
  • Iron Deficiency Anemia
  • IDA
  • Intravenous iron replacement therapy
  • Iron deficiency
  • Iron isomaltoside
  • Ferric derisomaltose
  • Monofer
  • Monoferric
  • Monover
  • Monofar
  • Monoferro
  • Hypophosphatemia
  • Ferric carboxymaltose
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects diagnosed with IDA, caused by different aetiologies
  • (Hb) ≤ 11 g/dL
  • Body weight > 50 kg
  • Serum ferritin (S-ferritin) \< 100 ng/mL
  • Estimated (eGFR) ≥ 65 mL/min/1.73 m2
  • Serum phosphate (S-phosphate) > 2.5 mg/dL
  • Intolerance or unresponsiveness to oral iron
  • Willingness to participate and signing the Form (ICF)

Exclusion criteria

Exclusion Criteria include:

  • Acute bleeding > 500 mL within 72 hours
  • Anaemia predominantly caused by factors other than IDA
  • Hemochromatosis or other iron storage disorders
  • Previous serious reactions to any IV iron compounds
  • Treatment with IV iron within the last 30 days prior to screening
  • Treatment with erythropoietin or erythropoietin-stimulation agents
  • Red blood cell transfusion, radiotherapy, and/or chemotherapy
  • Received an drug within the last 30 days prior to screening
  • Planned surgical procedure within the trial period
  • Hepatic enzymes > 3 times
  • Surgery under anaesthetic within the last 30 days prior to screening
  • Any non-viral infection within the last 30 days prior to screening
  • Alcohol or drug abuse within the past 6 months
  • Vitamin D deficiency
  • Untreated hyperparathyroidism
  • Kidney transplantation
  • Active malignant disease, disease-free for less than 5 years
  • History of a psychological illness or seizures
  • Pregnant or nursing women.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Iron isomaltoside/ferric derisomaltose

    Administered IV

    Drug: Iron isomaltoside/ferric derisomaltose

  • Active comparator
    Ferric carboxymaltose

    Administered IV

    Drug: Ferric carboxymaltose

Interventions

  • DrugIron isomaltoside/ferric derisomaltose

    Drug page: Iron isomaltoside 1000

    Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial. The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg).

    Also known as: Monofer®, Monoferric®, Monover®, Monofar®, Monoferro®

  • Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial. Ferric carboxymaltose was administered as 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg).

    Also known as: Injectafer®, Ferinject®

06

What researchers measure

Primary outcomes

  1. Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL)

    Safety The incidence of hypophosphatemia (defined as s-phosphate \<2 mg/dL) at any time from baseline up to day 35.

    Time frame: Baseline to day 35

Secondary outcomes

  1. Time With Hypophosphatemia ( S-phosphate Level <2.0 mg/dL)

    Safety Time with hypophosphatemia (i.e. time with s-phosphate level \< 2.0 mg/dL) from baseline up to day 35. The time with hypophosphatemia was calculated as the actual number of days from the first day where s-phosphate was \<2 mg/dL until the first day when s-phosphate was ≥2 mg/dL. If the subject did not reach s-phosphate ≥2 mg/dL, the subject was regarded as censored on day 35.

    Time frame: Baseline to day 35

  2. Proportion of Subjects With Hypophosphatemia on Day 35 ( S-phosphate Level <2.0 mg/dL)

    Safety Evaluate the proportion of subjects with hypophosphatemia (s-phosphate level \<2.0 mg/dL) on day 35.

    Time frame: Baseline to day 35

  3. Absolute [∆] Changes in S-phosphate From Baseline to Day 1, 7, 8, 14, 21, and 35

    Safety Absolute \[∆\] changes in s-phosphate from baseline to day 1, 7, 8, 14, 21, and 35.

    Time frame: Baseline, days 1, 7, 8, 14, 21, and 35

  4. Relative [%] Changes in S-phosphate From Baseline to Day 1, 7, 8, 14, 21, and 35

    Safety Relative \[%\] changes in s-phosphate from baseline to day 1, 7, 8, 14, 21, and 35.

    Time frame: Baseline, days 1, 7, 8, 14, 21, and 35

  5. Change From Baseline in Fractional Phosphate Urinary Excretion

    Safety Change in absolute fractional phosphate urinary excretion from baseline to days 1, 7, 8, 14, 21, and 35. Fractional excretion of phosphate (FEPi) is calculated as (\[phosphate in urine X creatinine in serum\]/\[phosphate in serum X creatinine in urine\]) X 100, and the unit is %.

    Time frame: Baseline, days 1, 7, 8, 14, 21, and 35

  6. Change in Concentration of (Intact) Fibroblast Growth Factor 23 (iFGF23) From Baseline to Day 1, 7, 8, 14, 21, and 35

    Safety Change in concentration of (Intact) Fibroblast Growth Factor 23 (iFGF23) from baseline to day 1, 7, 8, 14, 21, and 35.

    Time frame: Baseline, days 1, 7, 8, 14, 21, and 35

  7. Change in C-terminal Fibroblast Growth Factor 23 (cFGF23) From Baseline to Days 1, 7, 8, 14, 21, and 35

    Safety Change in C-terminal Fibroblast Growth Factor 23 (cFGF23) from baseline to days 1, 7, 8, 14, 21, and 35.

    Time frame: Baseline, days 1, 7, 8, 14, 21, and 35

  8. Change in Vitamin 25-Hydroxyvitamin D (Vitamin D 25) From Baseline to Days 1, 7, 8, 14, 21, and 35

    Safety Change in vitamin 25-Hydroxyvitamin D (vitamin D 25) from baseline to days 1, 7, 8, 14, 21, and 35.

    Time frame: Baseline, days 1, 7, 8, 14, 21, and 35

  9. Change in 1,25-Dihydroxyvitamin D (Vitamin D 1.25) From Baseline to Days 1, 7, 8, 14, 21, and 35

    Safety Change in 1,25-Dihydroxyvitamin D (vitamin D 1.25) from baseline to days 1, 7, 8, 14, 21, and 35.

    Time frame: Baseline, days 1, 7, 8, 14, 21, and 35

  10. Change in 24,25-Dihydroxyvitamin D (Vitamin D 24.25) From Baseline to Days 1, 7, 8, 14, 21, and 35

    Safety Change in 24,25-Dihydroxyvitamin D (vitamin D 24.25) from baseline to days 1, 7, 8, 14, 21, and 35

    Time frame: Baseline, days 1, 7, 8, 14, 21, and 35

  11. Change in Intact Parathyroid Hormone (PTH) From Baseline to Days 1, 7, 8, 14, 21, and 35

    Safety Change in intact Parathyroid hormone (PTH) from baseline to days 1, 7, 8, 14, 21, and 35.

    Time frame: Baseline, days 1, 7, 8, 14, 21, and 35

  12. Change in Ionized Calcium From Baseline to Days 1, 7, 8, 14, 21, and 35

    Safety Change in ionized calcium from baseline to days 1, 7, 8, 14, 21, and 35.

    Time frame: Baseline, days 1, 7, 8, 14, 21, and 35

  13. Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions

    Safety For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated.

    Time frame: Baseline to day 35

  14. Change in Hemoglobin (Hb) Per Gram Iron From Baseline to Days 1, 7, 8, 14, 21, and 35

    Efficacy Change in hemoglobin (Hb) per gram iron from baseline to days 1, 7, 8, 14, 21, and 35.

    Time frame: Baseline, days 1, 7, 8, 14, 21, and 35

  15. Change in S-ferritin From Baseline to Days 1, 7, 8, 14, 21, and 35

    Efficacy Change in s-ferritin from baseline to days 1, 7, 8, 14, 21, and 35.

    Time frame: Baseline, days 1, 7, 8, 14, 21, and 35

  16. Change in Transferrin Saturation (TSAT) From Baseline to Days 1, 7, 8, 14, 21, and 35

    Efficacy Change in Transferrin Saturation (TSAT) from baseline to days 1, 7, 8, 14, 21, and 35. TSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron.

    Time frame: Baseline, days 1, 7, 8, 14, 21, and 35

07

Results

Posted Feb 25, 2020

Participant flow

A total of 310 subjects were screened and 123 subjects were randomised into the trial.

Participant flow — Overall Study
MilestoneIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Started6261
Safety analysis set6360
Completed5958
Not completed33
Withdrew: Withdrawal by subject12
Withdrew: Lost to follow-up21

Outcome measures

PrimaryIncidence of Hypophosphatemia (S-phosphate Level <2 mg/dL)

Safety The incidence of hypophosphatemia (defined as s-phosphate \<2 mg/dL) at any time from baseline up to day 35.

Time frame:
Baseline to day 35
Reported as:
Count of participants · Participants
Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL)
ParticipantsIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL)545
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): -67.0 · 95% CI -77.4 to -51.5Iron isomaltoside/ferric derisomaltose was compared to ferric carboxymaltose by estimation of the risk difference and the associated 95% CI, adjusting for strata (underlying disease and screening s-phosphate) using the Cochran-Mantel-Haenszel method.
SecondaryTime With Hypophosphatemia ( S-phosphate Level <2.0 mg/dL)

Safety Time with hypophosphatemia (i.e. time with s-phosphate level \< 2.0 mg/dL) from baseline up to day 35. The time with hypophosphatemia was calculated as the actual number of days from the first day where s-phosphate was \<2 mg/dL until the first day when s-phosphate was ≥2 mg/dL. If the subject did not reach s-phosphate ≥2 mg/dL, the subject was regarded as censored on day 35.

Time frame:
Baseline to day 35
Reported as:
Median · days
Time With Hypophosphatemia ( S-phosphate Level <2.0 mg/dL)
daysIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Time With Hypophosphatemia ( S-phosphate Level <2.0 mg/dL)15 (7 to 56)29 (21 to 42)
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Log Rank · p = 0.8979
SecondaryProportion of Subjects With Hypophosphatemia on Day 35 ( S-phosphate Level <2.0 mg/dL)

Safety Evaluate the proportion of subjects with hypophosphatemia (s-phosphate level \<2.0 mg/dL) on day 35.

Time frame:
Baseline to day 35
Reported as:
Count of participants · Participants
Proportion of Subjects With Hypophosphatemia on Day 35 ( S-phosphate Level <2.0 mg/dL)
ParticipantsIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Proportion of Subjects With Hypophosphatemia on Day 35 ( S-phosphate Level <2.0 mg/dL)124
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): -39.2 · 95% CI -52.2 to -23.3
SecondaryAbsolute [∆] Changes in S-phosphate From Baseline to Day 1, 7, 8, 14, 21, and 35

Safety Absolute \[∆\] changes in s-phosphate from baseline to day 1, 7, 8, 14, 21, and 35.

Time frame:
Baseline, days 1, 7, 8, 14, 21, and 35
Reported as:
Mean · mg/dL
Absolute [∆] Changes in S-phosphate From Baseline to Day 1, 7, 8, 14, 21, and 35
mg/dLIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Day 10.25 ± 0.55-0.24 ± 0.61
Day 7-0.06 ± 0.75-1.15 ± 0.63
Day 8-0.10 ± 0.77-1.15 ± 0.64
Day 14-0.04 ± 0.75-1.44 ± 0.83
Day 210.04 ± 0.69-1.02 ± 0.99
Day 350.24 ± 0.76-0.92 ± 0.85
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 0.48 · 95% CI 0.31 to 0.65
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 1.06 · 95% CI 0.85 to 1.27
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 1.03 · 95% CI 0.81 to 1.25
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 1.35 · 95% CI 1.10 to 1.60
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 1.03 · 95% CI 0.75 to 1.32
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 1.13 · 95% CI 0.86 to 1.39
SecondaryRelative [%] Changes in S-phosphate From Baseline to Day 1, 7, 8, 14, 21, and 35

Safety Relative \[%\] changes in s-phosphate from baseline to day 1, 7, 8, 14, 21, and 35.

Time frame:
Baseline, days 1, 7, 8, 14, 21, and 35
Reported as:
Mean · Percentage change from baseline
Relative [%] Changes in S-phosphate From Baseline to Day 1, 7, 8, 14, 21, and 35
Percentage change from baselineIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Day 19.31 ± 18.98-5.94 ± 16.59
Day 70.55 ± 23.15-33.68 ± 17.53
Day 8-0.95 ± 24.02-34.03 ± 17.61
Day 141.13 ± 25.21-42.59 ± 24.81
Day 212.85 ± 22.66-30.11 ± 30.79
Day 359.69 ± 24.55-27.58 ± 27.47
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 15.55 · 95% CI 10.32 to 20.79
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 33.23 · 95% CI 26.62 to 39.84
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 32.78 · 95% CI 25.71 to 39.84
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 42.11 · 95% CI 33.89 to 50.32
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 32.28 · 95% CI 23.09 to 41.48
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 36.06 · 95% CI 27.33 to 44.78
SecondaryChange From Baseline in Fractional Phosphate Urinary Excretion

Safety Change in absolute fractional phosphate urinary excretion from baseline to days 1, 7, 8, 14, 21, and 35. Fractional excretion of phosphate (FEPi) is calculated as (\[phosphate in urine X creatinine in serum\]/\[phosphate in serum X creatinine in urine\]) X 100, and the unit is %.

Time frame:
Baseline, days 1, 7, 8, 14, 21, and 35
Reported as:
Mean · percentage excreted
Change From Baseline in Fractional Phosphate Urinary Excretion
percentage excretedIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Day 1-1.73 ± 4.852.44 ± 5.09
Day 70.56 ± 8.308.12 ± 9.16
Day 81.21 ± 7.719.08 ± 11.30
Day 140.10 ± 7.3411.46 ± 13.53
Day 210.78 ± 9.469.43 ± 12.33
Day 35-1.97 ± 7.294.90 ± 11.07
SecondaryChange in Concentration of (Intact) Fibroblast Growth Factor 23 (iFGF23) From Baseline to Day 1, 7, 8, 14, 21, and 35

Safety Change in concentration of (Intact) Fibroblast Growth Factor 23 (iFGF23) from baseline to day 1, 7, 8, 14, 21, and 35.

Time frame:
Baseline, days 1, 7, 8, 14, 21, and 35
Reported as:
Mean · pg/mL
Change in Concentration of (Intact) Fibroblast Growth Factor 23 (iFGF23) From Baseline to Day 1, 7, 8, 14, 21, and 35
pg/mLIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Day 1-2.7 ± 28.6103.6 ± 89.5
Day 76.8 ± 26.970.3 ± 78.4
Day 84.9 ± 25.2305.9 ± 262.3
Day 14-8.6 ± 25.7106.1 ± 114.9
Day 21-0.9 ± 39.766.7 ± 96.6
Day 35-10.5 ± 25.634.7 ± 64.2
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): -105.74 · 95% CI -131.04 to -80.45
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): -60.76 · 95% CI -82.95 to -38.58
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): -293.23 · 95% CI -368.15 to -218.30
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): -117.47 · 95% CI -151.60 to -83.33
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): -71.21 · 95% CI -101.80 to -40.61
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): -37.16 · 95% CI -54.92 to -19.39
SecondaryChange in C-terminal Fibroblast Growth Factor 23 (cFGF23) From Baseline to Days 1, 7, 8, 14, 21, and 35

Safety Change in C-terminal Fibroblast Growth Factor 23 (cFGF23) from baseline to days 1, 7, 8, 14, 21, and 35.

Time frame:
Baseline, days 1, 7, 8, 14, 21, and 35
Reported as:
Mean · RU/mL
Change in C-terminal Fibroblast Growth Factor 23 (cFGF23) From Baseline to Days 1, 7, 8, 14, 21, and 35
RU/mLIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Day 1-742.3 ± 800.7-390.2 ± 665.7
Day 7-723.6 ± 801.6-477.5 ± 652.0
Day 8-648.9 ± 757.5-284.2 ± 638.6
Day 14-717.9 ± 798.2-401.5 ± 661.5
Day 21-678.1 ± 783.5-458.9 ± 658.9
Day 35-660.1 ± 806.7-481.3 ± 653.7
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): -99.1 · 95% CI -136.42 to -61.76
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): -49.3 · 95% CI -72.80 to -25.90
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): -191.3 · 95% CI -242.47 to -140.09
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): -100.7 · 95% CI -137.19 to -64.20
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): -48.4 · 95% CI -71.78 to -24.96
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.1411 · Mean difference (final values): -15.0 · 95% CI -35.04 to 5.06
SecondaryChange in Vitamin 25-Hydroxyvitamin D (Vitamin D 25) From Baseline to Days 1, 7, 8, 14, 21, and 35

Safety Change in vitamin 25-Hydroxyvitamin D (vitamin D 25) from baseline to days 1, 7, 8, 14, 21, and 35.

Time frame:
Baseline, days 1, 7, 8, 14, 21, and 35
Reported as:
Mean · ng/mL
Change in Vitamin 25-Hydroxyvitamin D (Vitamin D 25) From Baseline to Days 1, 7, 8, 14, 21, and 35
ng/mLIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Day 10.04 ± 2.260.32 ± 2.26
Day 70.81 ± 3.34-0.94 ± 3.93
Day 80.32 ± 3.35-0.07 ± 5.07
Day 140.71 ± 5.17-1.29 ± 5.14
Day 210.78 ± 6.03-0.90 ± 4.70
Day 35-0.24 ± 6.44-0.72 ± 4.34
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.5620 · Mean difference (final values): -0.24 · 95% CI -1.08 to 0.59
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0126 · Mean difference (final values): 1.75 · 95% CI 0.38 to 3.12
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.6080 · Mean difference (final values): 0.42 · 95% CI -1.19 to 2.02
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0379 · Mean difference (final values): 2.09 · 95% CI 0.12 to 4.05
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.2368 · Mean difference (final values): 1.17 · 95% CI -0.78 to 3.12
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.8287 · Mean difference (final values): -0.22 · 95% CI -2.18 to 1.75
SecondaryChange in 1,25-Dihydroxyvitamin D (Vitamin D 1.25) From Baseline to Days 1, 7, 8, 14, 21, and 35

Safety Change in 1,25-Dihydroxyvitamin D (vitamin D 1.25) from baseline to days 1, 7, 8, 14, 21, and 35.

Time frame:
Baseline, days 1, 7, 8, 14, 21, and 35
Reported as:
Mean · pg/mL
Change in 1,25-Dihydroxyvitamin D (Vitamin D 1.25) From Baseline to Days 1, 7, 8, 14, 21, and 35
pg/mLIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Day 15.13 ± 13.05-20.57 ± 17.56
Day 7-19.92 ± 24.57-38.84 ± 20.86
Day 8-16.07 ± 25.10-39.63 ± 27.11
Day 14-3.31 ± 15.93-39.04 ± 27.46
Day 21-3.37 ± 16.45-28.89 ± 30.06
Day 35-3.86 ± 20.08-17.94 ± 26.15
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 24.27 · 95% CI 18.81 to 29.73
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 15.75 · 95% CI 8.83 to 22.67
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 20.14 · 95% CI 12.07 to 28.22
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 32.22 · 95% CI 25.49 to 38.96
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 22.87 · 95% CI 14.79 to 30.95
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0043 · Mean difference (final values): 10.60 · 95% CI 3.39 to 17.82
SecondaryChange in 24,25-Dihydroxyvitamin D (Vitamin D 24.25) From Baseline to Days 1, 7, 8, 14, 21, and 35

Safety Change in 24,25-Dihydroxyvitamin D (vitamin D 24.25) from baseline to days 1, 7, 8, 14, 21, and 35

Time frame:
Baseline, days 1, 7, 8, 14, 21, and 35
Reported as:
Mean · ng/mL
Change in 24,25-Dihydroxyvitamin D (Vitamin D 24.25) From Baseline to Days 1, 7, 8, 14, 21, and 35
ng/mLIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Day 1-0.02 ± 0.410.13 ± 0.51
Day 70.30 ± 0.490.72 ± 0.78
Day 80.19 ± 0.690.71 ± 0.84
Day 140.13 ± 0.600.95 ± 0.98
Day 210.12 ± 0.930.75 ± 0.93
Day 350.06 ± 0.890.60 ± 0.99
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0552 · Mean difference (final values): -0.17 · 95% CI -0.34 to 0.00
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0023 · Mean difference (final values): -0.37 · 95% CI -0.60 to -0.13
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0008 · Mean difference (final values): -0.51 · 95% CI -0.80 to -0.21
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): -0.80 · 95% CI -1.11 to -0.49
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0006 · Mean difference (final values): -0.64 · 95% CI -1.01 to -0.28
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0014 · Mean difference (final values): -0.59 · 95% CI -0.94 to -0.23
SecondaryChange in Intact Parathyroid Hormone (PTH) From Baseline to Days 1, 7, 8, 14, 21, and 35

Safety Change in intact Parathyroid hormone (PTH) from baseline to days 1, 7, 8, 14, 21, and 35.

Time frame:
Baseline, days 1, 7, 8, 14, 21, and 35
Reported as:
Mean · pg/mL
Change in Intact Parathyroid Hormone (PTH) From Baseline to Days 1, 7, 8, 14, 21, and 35
pg/mLIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Day 1-1.3 ± 20.20.7 ± 21.3
Day 7-4.6 ± 26.67.8 ± 26.6
Day 81.8 ± 27.92.6 ± 29.2
Day 143.2 ± 30.616.7 ± 33.7
Day 21-3.1 ± 22.817.2 ± 34.9
Day 350.2 ± 27.922.1 ± 41.2
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.7447 · Mean difference (final values): -1.13 · 95% CI -7.96 to 5.71
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0363 · Mean difference (final values): -9.70 · 95% CI -18.78 to -0.63
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.9242 · Mean difference (final values): -0.49 · 95% CI -10.56 to 9.59
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0602 · Mean difference (final values): -11.17 · 95% CI -22.84 to 0.49
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0008 · Mean difference (final values): -18.20 · 95% CI -28.68 to -7.73
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0031 · Mean difference (final values): -19.79 · 95% CI -32.75 to -6.83
SecondaryChange in Ionized Calcium From Baseline to Days 1, 7, 8, 14, 21, and 35

Safety Change in ionized calcium from baseline to days 1, 7, 8, 14, 21, and 35.

Time frame:
Baseline, days 1, 7, 8, 14, 21, and 35
Reported as:
Mean · mg/dL
Change in Ionized Calcium From Baseline to Days 1, 7, 8, 14, 21, and 35
mg/dLIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Day 10.04 ± 0.180.00 ± 0.20
Day 70.02 ± 0.16-0.07 ± 0.22
Day 80.03 ± 0.19-0.03 ± 0.20
Day 140.02 ± 0.22-0.08 ± 0.22
Day 210.08 ± 0.19-0.03 ± 0.21
Day 350.02 ± 0.21-0.03 ± 0.20
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.2670 · Mean difference (final values): 0.037 · 95% CI -0.029 to 0.104
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0040 · Mean difference (final values): 0.085 · 95% CI 0.028 to 0.142
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0472 · Mean difference (final values): 0.064 · 95% CI 0.001 to 0.127
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0050 · Mean difference (final values): 0.101 · 95% CI 0.031 to 0.171
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0061 · Mean difference (final values): 0.101 · 95% CI 0.029 to 0.172
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.1282 · Mean difference (final values): 0.055 · 95% CI -0.016 to 0.126
SecondaryIncidence of Protocol-defined Serious or Severe Hypersensitivity Reactions

Safety For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated.

Time frame:
Baseline to day 35
Reported as:
Count of participants · Participants
Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions
ParticipantsIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions10
SecondaryChange in Hemoglobin (Hb) Per Gram Iron From Baseline to Days 1, 7, 8, 14, 21, and 35

Efficacy Change in hemoglobin (Hb) per gram iron from baseline to days 1, 7, 8, 14, 21, and 35.

Time frame:
Baseline, days 1, 7, 8, 14, 21, and 35
Reported as:
Mean · g/dL per g of iron
Change in Hemoglobin (Hb) Per Gram Iron From Baseline to Days 1, 7, 8, 14, 21, and 35
g/dL per g of ironIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Day 1-0.16 ± 1.290.28 ± 1.82
Day 70.65 ± 0.860.94 ± 1.49
Day 80.50 ± 1.140.64 ± 0.81
Day 141.55 ± 1.531.16 ± 0.90
Day 211.68 ± 1.401.44 ± 0.97
Day 352.16 ± 1.621.94 ± 1.02
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.4618 · Mean difference (final values): -0.22 · 95% CI -0.82 to 0.37
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.3660 · Mean difference (final values): -0.17 · 95% CI -0.54 to 0.20
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.8580 · Mean difference (final values): 0.02 · 95% CI -0.25 to 0.30
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0257 · Mean difference (final values): 0.40 · 95% CI 0.05 to 0.74
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0016 · Mean difference (final values): 0.48 · 95% CI 0.19 to 0.77
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0185 · Mean difference (final values): 0.42 · 95% CI 0.07 to 0.76
SecondaryChange in S-ferritin From Baseline to Days 1, 7, 8, 14, 21, and 35

Efficacy Change in s-ferritin from baseline to days 1, 7, 8, 14, 21, and 35.

Time frame:
Baseline, days 1, 7, 8, 14, 21, and 35
Reported as:
Mean · ng/mL
Change in S-ferritin From Baseline to Days 1, 7, 8, 14, 21, and 35
ng/mLIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Day 182.0 ± 58.394.7 ± 62.4
Day 7261.7 ± 184.2289.5 ± 173.0
Day 8248.1 ± 182.4325.8 ± 220.1
Day 14133.9 ± 109.9352.9 ± 223.4
Day 2197.2 ± 127.6179.2 ± 135.0
Day 3546.8 ± 63.0108.9 ± 107.3
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.1922 · Mean difference (final values): -14.84 · 95% CI -37.26 to 7.57
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.5601 · Mean difference (final values): -18.28 · 95% CI -80.24 to 43.68
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0459 · Mean difference (final values): -71.02 · 95% CI -140.74 to -1.30
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): -207.33 · 95% CI -268.82 to -145.84
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0010 · Mean difference (final values): -78.60 · 95% CI -124.81 to -32.39
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0002 · Mean difference (final values): -58.79 · 95% CI -88.75 to -28.82
SecondaryChange in Transferrin Saturation (TSAT) From Baseline to Days 1, 7, 8, 14, 21, and 35

Efficacy Change in Transferrin Saturation (TSAT) from baseline to days 1, 7, 8, 14, 21, and 35. TSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron.

Time frame:
Baseline, days 1, 7, 8, 14, 21, and 35
Reported as:
Mean · percentage of saturation
Change in Transferrin Saturation (TSAT) From Baseline to Days 1, 7, 8, 14, 21, and 35
percentage of saturationIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Day 1118.9 ± 52.085.7 ± 40.4
Day 710.2 ± 34.812.9 ± 11.2
Day 86.3 ± 34.761.2 ± 43.0
Day 144.8 ± 32.616.4 ± 11.3
Day 216.8 ± 31.116.6 ± 11.7
Day 353.1 ± 32.314.7 ± 10.8
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): 40.82 · 95% CI 26.30 to 55.33
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.0089 · Mean difference (final values): 6.61 · 95% CI 1.69 to 11.53
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = <0.0001 · Mean difference (final values): -43.48 · 95% CI -54.92 to -32.03
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.3730 · Mean difference (final values): -1.68 · 95% CI -5.41 to 2.04
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.4778 · Mean difference (final values): -1.63 · 95% CI -6.15 to 2.90
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Mixed model for repeated measures · p = 0.3575 · Mean difference (final values): -1.73 · 95% CI -5.44 to 1.98
Post-hocIncidence of S-phosphate Level ≤1.0 mg/dL at Any Time From Baseline to Day 35

Safety Incidence of hypophosphatemia (defined as s-phosphate level ≤1 mg/dL) at any time from baseline up to day 35.

Time frame:
Baseline to day 35
Reported as:
Count of participants · Participants
Incidence of S-phosphate Level ≤1.0 mg/dL at Any Time From Baseline to Day 35
ParticipantsIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Incidence of S-phosphate Level ≤1.0 mg/dL at Any Time From Baseline to Day 3507
Statistical analysis
  • Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose · Cochran-Mantel-Haenszel · p = 0.0050 · Risk difference (rd): -11.9 · 95% CI -20.1 to -3.6

Adverse events

Collected over From the time subjects signed the informed consent form (CRF) and until they completed the study, all adverse events (AEs) or serious adverse events (SAEs) were reported in the CRF. The actual study duration was 35 days (or shorted if the trial was discontinued). Overall, eligible subjects participated in the trial for approximately 9 weeks (including a 28-day screening period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Iron Isomaltoside/Ferric Derisomaltose0/63 (0%)1/63 (1.6%)0/63 (0%)
Ferric Carboxymaltose0/60 (0%)0/60 (0%)25/60 (41.7%)
Most frequent serious events
Most frequent serious events
EventIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
HypersensitivityImmune system disorders1/630/60
Most frequent other events
Most frequent other events
EventIron Isomaltoside/Ferric DerisomaltoseFerric Carboxymaltose
Blood phosphorus decreasedInvestigations0/6313/60
HypophosphatemiaMetabolism and nutrition disorders0/6312/60
NauseaGastrointestinal disorders0/634/60

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Iron Isomaltoside/Ferric DerisomaltoseFerric CarboxymaltoseTotal
<=18 years000
Between 18 and 65 years6054114
>=65 years369
Age, Continuous
Age, Continuous(years)Iron Isomaltoside/Ferric DerisomaltoseFerric CarboxymaltoseTotal
Mean43.9 ± 10.446.3 ± 11.645.1 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Iron Isomaltoside/Ferric DerisomaltoseFerric CarboxymaltoseTotal
Female6157118
Male235
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Iron Isomaltoside/Ferric DerisomaltoseFerric CarboxymaltoseTotal
Hispanic or Latino373673
Not Hispanic or Latino262450
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Iron Isomaltoside/Ferric DerisomaltoseFerric CarboxymaltoseTotal
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American221941
White383876
More than one race123
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Iron Isomaltoside/Ferric DerisomaltoseFerric CarboxymaltoseTotal
Black/American Indian011
White/American Indian112
Region of Enrollment
Region of Enrollment(participants)Iron Isomaltoside/Ferric DerisomaltoseFerric CarboxymaltoseTotal
United States6360123
Iron Deficiency Anaemia (IDA) due to gynaecological blood loss
Iron Deficiency Anaemia (IDA) due to gynaecological blood loss(Participants)Iron Isomaltoside/Ferric DerisomaltoseFerric CarboxymaltoseTotal
Yes414283
No221840

2 further baseline measures are reported on the registry.

08

Study locations

16 sites
  • Pharmacosmos Investigational Site
    Los Angeles, California 90036, United States
  • Pharmacosmos Investigational Site
    Sacramento, California 95831, United States
  • Pharmacosmos Investigational Site
    Santa Ana, California 92704, United States
  • Pharmacosmos Investigational Site
    Clearwater, Florida 33759, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33125, United States
  • Pharmacosmos Investigational Site 1
    Miami, Florida 33126, United States
  • Pharmacosmos Investigational Site 2
    Miami, Florida 33126, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33143, United States
  • Pharmacosmos Investigational Site
    Miami, Florida 33144, United States
  • Pharmacosmos Investigational Site
    Indianapolis, Indiana 46202, United States
  • Pharmacosmos Investigational Site
    Wichita, Kansas 67206, United States
  • Pharmacosmos Investigational Site
    Metairie, Louisiana 70001, United States
  • Pharmacosmos Investigational Site
    Lancaster, Pennsylvania 17605, United States
  • Pharmacosmos Investigational Site
    Houston, Texas 77024, United States
  • Pharmacosmos Investigational Site
    Orem, Utah 84058, United States
  • Pharmacosmos Investigational Site
    Leesburg, Virginia 20176, United States
09

References and documents

Publications

  • Wolf M, Rubin J, Achebe M, Econs M, Peacock M, Imel E, Thomsen L, Carpenter T, Weber T, Zoller H. Effects of iron isomaltoside versus ferric carboxymaltose on hormonal control of phosphate homeostasis: The PHOSPHARE-IDA04/05 randomized controlled trials. Journal of the Endocrine Society, Volume 3, Issue Supplement_1, April-May 2019, OR13-3, https://doi.org/10.1210/js.2019-OR13-3
  • Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, Thomsen LL, Carpenter TO, Weber T, Brandenburg V, Zoller H. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA. 2020 Feb 4;323(5):432-443. doi: 10.1001/jama.2019.22450. PubMed 32016310 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Jun 2018, 7 months.

Results were first posted in Feb 2020, 1 year 8 months after primary completion. A results delay was requested in May 2019.

Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2017
First posted
Aug 3, 2017
StartActual
Oct 24, 2017
Primary completionActual
Jun 19, 2018
CompletionActual
Jun 19, 2018
Results delay requested
May 22, 2019
Results first posted
Feb 25, 2020
Last update
Feb 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03238911
Lead sponsor
Pharmacosmos A/S
Responsible party
Sponsor
First posted
Aug 3, 2017
Start date
Oct 24, 2017
Primary completion
Jun 19, 2018
Completion
Jun 19, 2018
Results posted
Feb 25, 2020
Last update
Feb 25, 2020

Study contacts

Pharmacosmos A/S Clinical and Non-clinical Research
study director · Pharmacosmos A/S

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion